**Supplementary Table 6. Distribution differences in PIM use between men and women classified by ATC classification system 1st level group**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| ATC-group | Number of PIMs used by men(N=166) | Number of PIMs used by women(N=236) | P-value | Number of PIMs overall(N=402) |
| Alimentary tract and metabolismRanitidineMebeverineMetoclopramide1Alizapride1Sodium picosulfateAloeGlibenclamideGlimepirideSitagliptineVildagliptine | 25 (15.1%)4 (2.4%)-1 (0.6%)---2 (1.2%)11 (6.6%)6 (3.6%)1 (0.6%) | 22 (9.3%)2 (0.8%)2 (0.8%)4 (1.7%)1 (0.4%)2 (0.8%)1 (0.4%)2 (0.8%)5 (2.1%)2 (0.8%)1 (0.4) | 0.078 | 47 (11.7%)6 (1.5%)2 (0.5%)5 (1.2%)1 (0.2%)2 (0.5%)1 (0.2%)4 (1.0%)16 (4.0%)8 (2.0%)2 (0.5%) |
| Blood and blood forming organsDipyridamoleDabigatranRivaroxaban | 4 (2.4%)1 (0.6%)2 (1.2%)1 (0.6%) | 2 (0.8%)-1 (0.4%)1 (0.4% | - | 6 (1.5%)1 (0.2%)3 (0.7%)2 (0.5%) |
| Cardiovascular systemDigitoxinDigoxinFlecainideAmiodaroneDronedaroneMoxonidineDoxazosinSpironolactone (>25mg/d)AescinPropranololSotalolNifedipineVerapamilNiacin | 34 (20.5%)6 (3.6%)-2 (1.2%)2 (1.2%)--2 (1.2%)6 (3.6%)1 (0.6%)2 (1.2%)1 (0.6%)4 (2.4%)6 (3.6%)2 (1.2%) | 30 (12.7%)1 (0.4%)1 (0.4%)--1 (0.4%)6 (2.5%)2 (0.8%)2 (0.8%)-2 (0.8%)-2 (0.8%)12 (5.1%)1 (0.4%) | 0.036\* | 64 (15.9%)7 (1.7%)1 (0.2%)2 (0.5%)2 (0.5%)1 (0.2%)6 (1.5%)4 (1.0%)8 (2.0%)1 (0.2%)4 (1.0%)1 (0.2%)6 (1.5%)18 (4.5%)3 (0.7%) |
| Genito-urinary system, sex hormonesEstrogens (oral)Oxybutynine1Tolterodine1Solifenacin1Trospium1Darifenacin1Fesoterodin1 | 10 (6.0%)--1 (0.6%)3 (1.8%)3 (1.8%)2 (1.2%)1 (0.6%) | 46 (19.5%)37 (15.7%)3 (1.3%)1 (0.4%)2 (0.8%)1 (0.4%)2 (0.8%)- | < 0.001\* | 56 (13.9%)37 (9.2%)3 (0.7%)2 (0.5%)5 (1.2%)4 (1.0%)4 (1.0%)1 (0.2%) |
| Musculo-skeletal systemIndometacinDiclofenacMeloxicamIbuprofen (>3\*400mg/d or longer than one week)KetoprofenCelecoxibEtoricoxibTetrazepam1 | 38 (22.9%)1 (0.6%)22 (13.3%)-6 (3.6%)1 (0.6%)1 (0.6%)5 (3.0%)2 (1.2%) | 61 (25.8%)2 (0.8%)37 (15.7%)3 (1.3%)10 (4.2%)-3 (1.3%)5 (2.1%)1 (0.4%) | 0.498 | 99 (24.6%)3 (0.7%)59 (14.7%)3 (0.7%)16 (6.8%)1 (0.2%)4 (1.0%)10 (2.5%)3 (0.7%) |
| Nervous systemTramadolAcetylsalicylic acid (>325mg/d)TriptanesClonazepam1RopinirolePramipexoleCabergolinePiribedilRotigotineOlanzapine1 (>10mg/d)LithiumDiazepam1Bromazepam1Lormetazepam1 (>0.5mg/d)Zopiclone1 (> 3.75mg/d)Zolpidem1 (> 5mg/d)Clomipramine1Trimipramine1Amitriptyline1Doxepin1FluoxetineParoxetineBupropionVenlafaxinePiracetamGinkgo biloba | 50 (30.1%)1 (0.6%)7 (4.2%)2 (1.2%)2 (1.2%)-2 (1.2%)1 (0.6%)1 (0.6%)-1 (0.6%)2 (1.2%)1 (0.6%)--1 (0.6%)2 (1.2%)-1 (0.6%)2 (1.2%)1 (0.6%)4 (2.4%)1 (0.6%)-7 (4.2%)-11 (6.6%) | 67 (28.4%)4 (1.7%)11 (4.7%)4 (1.7%)1 (0.4%)1 (0.4%)1 (0.4%)--2 (0.8%)-1 (0.4%)3 (1.3%)1 (0.4%)1 (0.4%)2 (0.8%)4 (1.7%)1 (0.4%)2 (0.8%)4 (1.7%)4 (1.7%)2 (0.8%)1 (0.4%)1 (0.4%)3 (1.3%)1 (0.4%)12 (5.1%) | 0.707 | 117 (29.1%)5 (1.2%)18 (4.5%)6 (1.5%)3 (0.7%)1 (0.2%)3 (0.7%)1 (0.2%)1 (0.2%)2 (0.5%)1 (0.2%)3 (0.7%)4 (1.0%)1 (0.2%)1 (0.2%)3 (0.7%)6 (1.5%)1 (0.2%)3 (0.7%)6 (1.5%)5 (1.2%)6 (1.5%)2 (0.5%)1 (0.2%)10 (2.5%)1 (0.2%)23 (5.7%) |
| Respiratory systemTheophyllineDiphenhydramine1Doxylamine1Dimetindene1Promethazine1 | 5 (3.0%)2 (1.2%)2 (1.2%)1 (0.6%)-- | 8 (3.4%)1 (0.4%)2 (0.8%)3 (1.3%)1 (0.4%)1 (0.4%) | 0.833 | 13 (3.2%)3 (0.7%)4 (1.0%)4 (1.0%)1 (0.2%)1 (0.2%) |
| Overall substances with anticholinergic effects  | 27 (16.3%) | 45 (19.1%) | 0.471 | 72 (17.9%) |

Notes and abbreviations; ATC-group 1st level, chemical substances and numbers of PIMs used by men and women, 1anticholinergic side effects possible (EU(7)-PIM).

ATC, Anatomical Therapeutic Chemical